Jonathan Douse
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Internal Medicine top 10%
- Venous Thromboembolism Diagnosis and Management
Papers in
-
- COVID-19 Clinical Research Studies 5
-
- Lung Cancer Diagnosis and Treatment 1
- Co-authors
- Catherine Read (1 shared paper)Stephen G Spiro (1 shared paper)Sam M. Janes (1 shared paper)
- Partner nations
- United KingdomVietnamNepal
In The Last Decade
Jonathan Douse
6 papers receiving 1.2k citations
Jonathan Douse's Hit Papers
Peers
Comparison fields: 5 of 76
- Infectious Diseases 949
- Internal Medicine 27
- Oncology 60
- Hematology 36
- Statistics and Probability 32
Countries citing papers authored by Jonathan Douse
This map shows the geographic impact of Jonathan Douse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Douse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Douse more than expected).
Fields of papers citing papers by Jonathan Douse
This network shows the impact of papers produced by Jonathan Douse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Douse. The network helps show where Jonathan Douse may publish in the future.
Co-authors
The 3 scholars most cited alongside Jonathan Douse, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 2 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 3 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 4 | 2021 | 213 | |
| 5 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 6 | 2008 | 22 |
About Jonathan Douse
Jonathan Douse is a scholar working on Infectious Diseases, Pulmonary and Respiratory Medicine, Nuclear Energy and Engineering, Waste Management and Disposal and Organic Chemistry, having authored 6 papers that have together received 1.2k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (5 papers) and Lung Cancer Diagnosis and Treatment (1 paper). The work is most often cited by research in Infectious Diseases (949 citations), Internal Medicine (27 citations), Oncology (60 citations), Hematology (36 citations) and Statistics and Probability (32 citations). Jonathan Douse has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Frequent co-authors include Catherine Read, Stephen G Spiro and Sam M. Janes. Their work appears in journals such as The Lancet and Seminars in Respiratory and Critical Care Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.